Magdalene Cook, M.D., has more than 20 years of experience as an executive, investor and advisor within the life sciences industry across several therapeutic areas with a recent focus on rare diseases and gene therapy. She most recently served as the chief executive officer of Renovacor, a rare disease cardiovascular gene therapy company, where she launched the company in partnership with the academic founder and scaled the company to a fully integrated biotechnology organization, financed through an IPO in 2021 and subsequently sold to Rocket Pharmaceuticals in 2022. Prior to joining Renovacor Dr. Cook served as a strategic advisor to life science investment firms and start-up companies and entrepreneurs, offering guidance on due diligence for new programs, company building, fundraising and business development opportunities. Before that, Dr. Cook was a principal at Aisling Capital, a life sciences focused investment firm based in New York City. Dr. Cook has served on the board of directors of public and private life sciences companies over the past 20 years.
Dr. Cook holds a M.D. from Columbia University College of Physicians & Surgeons and a B.A. in Interdisciplinary Studies from the University of Virginia, where she was an Echols Scholar.